Conference Coverage

Dual kinase inhibitor performs well in its first safety, efficacy study for atopic dermatitis

Publish date: February 24, 2018

 

REPORTING FROM AAD 2018

SOURCE: Bissonnette R et al. AAD 2018, Abstract 6777

Pages

Recommended Reading

Eye disease affects 1 in 5 adults with severe atopic dermatitis
MDedge Internal Medicine
Adverse effects low in long-term crisaborole eczema study
MDedge Internal Medicine
International survey sheds new light on adult atopic dermatitis
MDedge Internal Medicine
JAK inhibitors for atopic dermatitis might hit JAK-pot
MDedge Internal Medicine
Systemic corticosteroids not recommended for long-term treatment of eczema
MDedge Internal Medicine
Antihistamines still are prescribed inappropriately for atopic dermatitis
MDedge Internal Medicine
VIDEO: Dupilumab or cyclosporine for treating atopic dermatitis?
MDedge Internal Medicine
Upadacitinib calms itch, clears skin in moderate to severe atopic dermatitis
MDedge Internal Medicine
Anti–IL-33 antibody stakes a first-in-class claim on moderate to severe atopic dermatitis
MDedge Internal Medicine
VIDEO: With new therapies available, it’s the ‘decade of eczema,’ researcher says
MDedge Internal Medicine